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Abstract
Background: From in vitro studies, it has become clear that several signaling cascades are involved
in angiotensin II-induced cellular hypertrophy. The aim of the present study was to determine some
of the signaling pathways mediating angiotensin II (Ang II)-induced protein synthesis in vivo in large
and small arteries.
Methods:  Newly synthesized proteins were labeled during 4 hours with tritiated leucine in
conscious control animals, or animals infused for 24 hours with angiotensin II (400 ng/kg/min).
Hemodynamic parameters were measure simultaneously. Pharmacological agents affecting signaling
cascades were injected 5 hours before the end of Ang II infusion.
Results: Angiotensin II nearly doubled the protein synthesis rate in the aorta and small mesenteric
arteries, without affecting arterial pressure. The AT1 receptor antagonist Irbesartan antagonized
the actions of Ang II. The Ang II-induced protein synthesis was associated with increased
extracellular signal-regulated kinases (ERK)1/2 phosphorylation in aortic, but not in mesenteric
vessels. Systemic administration of PD98059, an inhibitor of the ERK-1/2 pathway, produced a
significant reduction of protein synthesis rate in the aorta, and only a modest decrease in
mesenteric arteries. Rapamycin, which influences protein synthesis by alternative signaling, had a
significant effect in both vessel types. Rapamycin and PD98059 did not alter basal protein synthesis
and had minimal effects on arterial pressure.
Conclusion:  ERK1/2 and rapamycin-sensitive pathways are involved in pressure-independent
angiotensin II-induced vascular protein synthesis in vivo. However, their relative contribution may
vary depending on the nature of the artery under investigation.
Published: 10 May 2004
BMC Cardiovascular Disorders 2004, 4:6
Received: 04 March 2004
Accepted: 10 May 2004
This article is available from: http://www.biomedcentral.com/1471-2261/4/6
© 2004 Daigle et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/6
Page 2 of 8
(page number not for citation purposes)
Background
Angiotensin II (Ang II) has an important role in the phys-
iological and pathophysiological regulation of the arterial
wall. Indeed, in addition to being a vasoactive peptide,
this multifunctional hormone stimulates hypertrophy of
isolated vascular smooth muscle cells (VSMC), as a result
of enhanced protein synthesis [1]. Chronic administra-
tion of Ang II has been shown to promote significant
changes in vascular structure, leading to pressure-inde-
pendent hypertrophic remodeling of small arteries [2-4].
In large arteries, exogenous Ang II induces hypertrophy
followed by increased DNA synthesis [5,6].
Binding of Ang II to the Ang II subtype 1 (AT1)-receptor
triggers a complex series of intracellular signaling events
activating protein kinase cascades acting synergistically to
increase the rate of global protein synthesis [7,8]. In vitro
studies identified at least two signaling pathways directly
linked to protein synthesis [9-11]. Activation of members
of the mitogen-activated protein kinase (MAPK) family, of
which extracellular signal-regulated kinase-1 (ERK-1 or
p44mapk) and ERK-2 (p42mapk) represent one of these
pathways [10,12]. Their threonine/tyrosine phosphoryla-
tion and activation by MEK can be pharmacologically
inhibited by the synthetic compound PD98059 [9,13,14].
Activation of the AT1 receptor also stimulates the phos-
phorylation and enzymatic activity of the 70-kD S6 kinase
(p70S6k) in VSMC [10], which is the major physiologic
kinase for ribosomal protein S6, a component of the 40S
ribosomal subunit [15]. p70S6k is implicated in Ang II-
induced protein synthesis in rat aortic VSMC and cardiac
myocytes [10,11]. Indeed, in vitro studies have shown that
rapamycin, an immunosuppressive agent, abolishes acti-
vation (phosphorylation) of p70S6k, and consequently of
protein synthesis [10,11].
Thus, although in vitro studies clearly indicate that Ang II
activates cascades involving ERK-1/2 and p70S6K, which
both contribute to enhance protein synthesis, little is
known about the in vivo contribution of these signaling
pathways to the vascular effect of Ang II. Furthermore, a
different contribution of signaling cascades in arteries
with different physiological function is a plausible
hypothesis that deserves investigation. These issues repre-
sent the aim of the present study and to address them, we
used a model that allows the measurement of vascular
protein synthesis in vivo. We then compared the efficacy of
PD98059 and rapamycin to modulate protein synthesis in
conduit (aorta) and resistance (small arteries from the
mesenteric circulation) vessels.
Methods
Animals and treatments
Male Sprague-Dawley rats weighing 300–325 g (obtained
from Charles River Laboratories, Que., Canada) were
anesthetized with pentobarbital sodium (65 mg/kg, i.p.)
for insertion of a polyethylene catheter (PE10 segment
welded to a PE50) into the femoral artery and vein. In
some animals, an osmotic pump (model 1003D Alzet®)
was simultaneously implanted subcutaneously in the sub-
costal region, releasing a constant dose of 400 ng/kg/min
of Angiotensin II. Rats were then free to move and had
access to food and water, with a tethering system protect-
ing the catheters [16].
Twenty two hours after surgery, a saline solution contain-
ing L-(3,4-3H) leucine was infused i.v. for 4 hours at a rate
of 12 µCi/hour. Other pharmaceutical agents were admin-
istered by i.v. bolus injection following 21 hours of Angi-
otensin II infusion (one hour prior to [3H]-leucine
infusion). Ang II-treated rats received the synthetic com-
pound PD98059 at doses of 1 mg/kg (n = 6), 5 mg/kg (n
= 7) and 10 mg/kg (n = 6). A group of control rats received
10 mg/kg PD98059 (n = 4). In a second set of experi-
ments, rapamycin was injected at doses of 0.1 mg/kg (n =
8), 0.5 mg/kg (n = 6) and 1 mg/kg (n = 3) in Ang II-treated
rats. Six control rats received 0.5 mg/kg rapamycin. In a
third series, Ang II-treated rats received irbesartan, a selec-
tive AT-1 receptor blocker, at doses of 10 mg/kg (n = 9),
30 mg/kg (n = 5) and 40 mg/kg (n = 5), following the
same experimental protocol. Additional rats were treated
with irbesartan according to a different treatment scheme:
Irbesartan was administered subcutaneously at the time of
surgery and 12 hours later (10 mg/kg at each occasion) in
Ang II-treated (n = 8) or in control rats (n = 6). We used
two sets of control and Ang II-treated rats to confirm the
reproducibility of the method. The first set (n = 10 and 10,
respectively) was studied simultaneously with PD98059
and irbesartan groups. The second set (n = 7 and 9, respec-
tively) was studied in parallel with the rapamycin experi-
ments. Additional control (n = 3) and Ang II-treated (n =
3) rats were sacrificed 21 hours after the beginning of Ang
II administration, to determine ERK-1/2 phosphorylation
at the time when PD98059 was normally injected. Finally,
in 3 control and 3 rats treated for 5 hours with PD98059,
we confirmed the in vivo effectiveness of PD98059 to
reduce basal ERK-1/2 phosphorylation (data not shown).
Mean arterial pressure (MAP) was continuously measured
intra-arterially in freely moving rats 15 minutes before
and averaged for the 5 hours following drug administra-
tion. The animals were then anesthetized (pentobarital 35
mg/kg i.v.) and exsanguinated. The thoracic aorta and the
mesenteric vascular bed were collected and immediately
transferred in a modified cold Krebs-Ringer bicarbonate
solution (composition in mmol/L: NaCl 118.6; KCl 4.8;
CaCl2 2.5; MgSO4 1.2; KH2PO4 1.2; NaHCO3 25.1; Na+
2,
Ca2+-EDTA 0.026; glucose 10.1). The aorta and small ram-
ifications of the superior mesenteric artery (first order and
smaller) were freed from surrounding tissue and frozen inBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/6
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liquid nitrogen. The Animal Care and Use Committee at
the Université de Montréal approved all the study
protocols.
Protein synthesis measurement
In order to measure leucine incorporation in small and
conduit arteries, we used a method derived from that of
McNulty et al. [17]. Previous publications present addi-
tional experiments that validate the method in different
conditions, including Ang II infusion [18,19]. Briefly, tis-
sues were pulverized with dry ice and liquid nitrogen. Five
volumes 10% trichloroacetic acid (TCA) were added and
the samples were left overnight at 4°C. Tissues were then
rinsed once in the same amount of 10% TCA and twice in
water to wash non-incorporated leucine. The pellet was
solubilized in potassium hydroxide (KOH 1 M) and radi-
oactivity was measured. Results obtained are in cpm/mg
of tissue. The second portion of pulverized tissue was also
left overnight in 10% TCA, and then solubilized in
sodium hydroxide (NaOH 1 M) for measurement of pro-
tein content by the method described by Lowry [20].
Results obtained were in mg of proteins/mg of tissue. The
final data is expressed as CPM/mg protein and represents
the rate of protein synthesis over a 4-hour period.
Determination of ERK-1/2 phosphorylation
To confirm that Ang II stimulates the ERK-1/2 pathway
and that PD98059 is effective in vivo, ERK-1/2 phosphor-
ylation was determined in vascular tissues by western
blot, using a phosphospecific antibody, as previously
described [21].
Drugs and statistical analysis
All drugs were purchased from Calbiochem. Irbesartan
was a kind gift from Bristol-Myers Squibb. PD 98059 was
suspended in a 1% polymeric solution (Pluronic F68) and
sonicated (ultrasound) prior to administration. We previ-
ously confirmed that the vehicle had no effect on protein
synthesis. Rapamycin was suspended in 0.2% car-
boxymethylcellulose (CMC) by sonication, aliquoted and
frozen. Prior to its administration, rapamycin was further
diluted in CMC.
Data are presented as mean ± s.e.m. Statistical analysis
was done by ANOVA followed by Bonferroni's correction
for multiple comparisons. A priori comparisons were: Ang
II and drugs alone vs control, and drugs + Ang II vs Ang II
alone. P < 0.05 was considered significant.
Results
ERK-1/2 pathway
Angiotensin II increased the rate of protein synthesis by
72% in the aorta and by 80% in mesenteric arteries (Fig-
ure 1). At the dose used, Ang II administration did not ele-
vate arterial pressure as compared to control rats (Table
1). PD98059, a selective MEK inhibitor, had no signifi-
cant effect on aortic and mesenteric protein synthesis
when administered alone at 5 mg/kg (Figure 1). Given at
doses of 1 and 5 mg/kg, PD98059 had no significant effect
on Ang II-induced protein synthesis in the aorta and
mesenteric bed. At 10 mg/kg, the MEK inhibitor did not
produce a further reduction in protein synthesis in small
arteries, but totally blocked aortic Ang II-induced protein
synthesis (107% reduction). The effect obtained at 10 mg/
kg but not at smaller doses confirms that the vehicle, the
volume of which was the same for each injection, does not
alter protein synthesis. Antibodies directed against the
active (phosphorylated) form of ERK-1/2 confirmed that
their aortic activity doubled following Ang II administra-
tion (Figure 2). In contrast, however, ERK-1/2 activity was
not enhanced in mesenteric arteries. The acute adminis-
tration of PD98059 did not influence mean arterial pres-
sure averaged over the five hours following its
administration (Table 1).
Rapamycin-sensitive pathway
In this second series, Ang II enhanced aortic and
mesenteric protein synthesis by 91 and 105%, respectively
(Figure 3), confirming the reproducibility of our method.
When administered alone as an i.v. bolus, 0.5 mg/kg
rapamycin had no effect on protein synthesis in the
mesenteric bed, nor in the aorta (Figure 3). When protein
synthesis was first stimulated by Ang II, rapamycin pro-
duced a significant reduction in mesenteric arteries, reach-
ing a maximum of 84% at 0.5 mg/kg. As with PD98059,
the effect in the aorta improved further at the highest
dose, reaching 76% reduction at 1 mg/kg. The highest
dose of rapamycin increased mean arterial pressure by 10
mmHg averaged over the course of its administration
(Table 1).
AT-1 Receptor antagonism
Using the same protocol as in the previous experiments,
we administered irbesartan, a specific and selective AT1
receptor blocker, one hour prior to leucine infusion. In
both aorta and small mesenteric arteries, irbesartan at 10,
30 and 40 mg/kg had no significant effect on Ang II-
induced increase in protein synthesis (data not shown).
However, when administered at the beginning and 12
hours after the start of Ang II infusion (2 × 10 mg/kg),
irbesartan totally abolished the trophic effect of Ang II in
both vascular beds (Figure 4). In addition, irbesartan
administered alone had a tendency to reduce protein syn-
thesis in the aorta. This tendency reached statistical signif-
icance in the mesenteric arteries. The blood pressure
lowering effect of irbesartan was similar in both treatment
regimens (Table 1).BMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/6
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Discussion
Ang II is a potent trophic factor in several cell types,
including VSMC [1,10]. Chronic in vivo administration of
the peptide produces a pressure-independent hypertrophy
of the vascular wall [2-4,22]. Both hypertrophy and DNA
synthesis have been reported in large arteries, although
protein synthesis seems to precede DNA replication [5,6].
In agreement with ex vivo protein synthesis measurement
in tissues extracted from rats treated with Ang II [23], our
study demonstrates increased protein synthesis in vivo fol-
lowing Ang II administration in conduit and resistance
arteries. The enhanced protein synthesis occurred without
any significant change in arterial pressure, supporting the
concept that Ang II exerts a vascular trophic action inde-
pendently from pressure changes [2,4,22].
Angiotensin II initiates complex cellular signaling events,
and it appeared imperative to determine which pathways
are operative in vivo, while also examining for potential
vascular heterogeneity. The ERK1/2 pathway has been
implicated in Ang II-induced protein synthesis [9], and
the development of PD98059, which inhibits the phos-
phorylation and activation of ERK by MEK [9,13,14], has
been a key element to reveal these findings. We have pre-
viously reported that the highest dose of PD98059 inhib-
its basal and stimulated ERK 1/2 phosphorylation in vivo
[19]. Our results with the antagonist strongly suggest that
this pathway is an important pressure-independent com-
ponent of Ang II-induced elevation of aortic protein syn-
thesis  in vivo. The significant increase in ERK 1/2
phosphorylation following Ang II administration is also
in line with such an interpretation. However, in small
arteries PD98059 had only a modest effect on Ang II-
induced protein synthesis. This correlates well with the
apparent inability of Ang II to stimulate ERK-1/2 activity
in these vessels, as demonstrated in the present study. Our
results contrast those published recently, showing that
Ang II stimulates ERK 1/2 activity in small isolated
mesenteric arteries [24]. However, the time course was
very different (see discussion below).
Rapamycin is another compound that inhibits VSMC pro-
tein synthesis induced by several growth factors, including
Ang II [10,15]. In vivo administration of rapamycin several
hours after Ang II showed a marked inhibition of Ang II-
induced protein synthesis in mesenteric arteries and in the
aorta. This effect occurred without a reduction of arterial
pressure, such as seen with irbesartan. In fact, with the
highest dose of rapamycin arterial pressure was even ele-
vated, an effect which could explain the loss of a signifi-
cant reduction of protein synthesis in small arteries at this
dose. The low number of animals may also contribute to
the statistical outcome. Thus, the rapamycin-sensitive sig-
naling cascade is a second pathway mediating protein syn-
thesis in large arteries in vivo, but may be predominantly
responsible for the Ang II response in small arteries. One
likely explanation for the regional heterogeneity could be
related to differences in the machinery regulating protein
synthesis. ERK 1/2 appear to converge towards the
Effect of PD98059 (PD at 1, 5 and 10 mg/kg) on aortic and  mesenteric leucine incorporation (expressed in cpm/mg  protein) Figure 1
Effect of PD98059 (PD at 1, 5 and 10 mg/kg) on aortic and 
mesenteric leucine incorporation (expressed in cpm/mg pro-
tein). The effect of the drug was tested in basal conditions 
and after Angiotensin II (Ang)-induced protein synthesis. * P 
< 0.05 vs Control (Ctl); † P < 0.05 vs Ang II alone (ANOVA 
+ Bonferroni).
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activation of the mRNA 5' cap-binding protein eIF4E,
which seems to be the rate-limiting step in cap-dependent
mRNA translation [8,25]. In contrast, rapamycin inhibits
FRAP/mTOR, which lies in the cascade relaying phosphoi-
nositide 3-OH kinase (PI 3-K) to the phosphorylation and
inactivation eIF4E-binding protein (4E-BP1) [26] and to
the activation of the p70s6k, which also regulates the trans-
lation of a subset of mRNAs [27]. Thus, it is possible that
VSMC in different types of arteries, with distinct
physiological roles, may actually regulate their protein
synthesis by alternative mechanisms. The present study
only suggests this heterogeneity and a more appropriate
study will be designed to address this hypothesis, which
could be of future therapeutic importance. Indeed, differ-
ent relative cellular composition of the vessel wall could
also explain our observation.
In our in vivo conditions, ERK1/2 and rapamycin-sensitive
pathways seemed to overlap to a great extent in the aorta.
Considering the magnitude of inhibition by both drugs
alone, combination of PD98059 and rapamycin would
not provide additional information on the interdepend-
ence of the signaling events in vivo. An overlap of smaller
magnitude has also been reported in cell culture systems,
although the pathways were shown to be independent [9],
since rapamycin did not modify ERK1/2 activity [9]. How-
ever, a more recent study suggests that the ERK-1/2 path-
way could actually enhance p70s6k  phosphorylation
following Ang II administration, through EGF-receptor
transactivation [28]. It is not know if this translates into
enhanced protein synthesis, but our results seems
consistent with an interdependence of the two pathways
in the control of aortic protein synthesis.
The role of AT1-receptors mediating Ang II-induced pro-
tein synthesis was confirmed with irbesartan, a potent
AT1-receptor antagonist [29,30]. In addition, the results
Table 1: Mean arterial pressure before and after drug administration.
Treatment MAP: pre-drug (mm Hg)† MAP: post-drug (mm Hg)
Control 103 ± 5
Ang II 105 ± 7
Ang II + PD 1 mg/kg 122 ± 6 117 ± 10
Ang II + PD 5 mg/kg 119 ± 4 111 ± 5
Ang II + PD 10 mg/kg 115 ± 4 113 ± 2
Irb 2 × 10 mg/kg 75 ± 1
Ang II + Irb 2 × 10 mg/kg 84 ± 2
Control 112 ± 3
R 0.5 mg/kg 98 ± 10 95 ± 10
Ang II 114 ± 7
Ang II + R 0.1 mg/kg 101 ± 9 93 ± 9
Ang II + R 0.5 mg/kg 109 ± 4 109 ± 2
Ang II + R 1.0 mg/kg 111 ± 5 123 ± 1 *
Data are presented as mean ± sem * P < 0.05 vs Pre-drug (paired t-test). † For control and Angiotensin II-treated animals that did not receive 
further acute treatments, only one pressure is presented. MAP Pre-drug: mean arterial pressure before acute drug administration; MAP post-drug: 
MAP averaged during the 5 hours following acute drug administration; PD: PD98059; R: Rapamycin; Irb: Irbesartan.
Western blot analysis with a phosphospecific antibody of  protein samples prepared form three control aortas (Ctl-Ao,  lanes 1–3) and mesenteric arteries (Clt-Mes, lanes 4–6), and  three angiotensin II-treated aortas (Ang-Ao, lanes 7–9) and  mesenteric arteries (Ang-Mes, lanes 10–12) Figure 2
Western blot analysis with a phosphospecific antibody of 
protein samples prepared form three control aortas (Ctl-Ao, 
lanes 1–3) and mesenteric arteries (Clt-Mes, lanes 4–6), and 
three angiotensin II-treated aortas (Ang-Ao, lanes 7–9) and 
mesenteric arteries (Ang-Mes, lanes 10–12). The bar chart 
represents the mean optical density (O.D.) of the three 
experiments for both ERK-1 (p44mapk) and ERK-2 (p42mapk) 
in control (open bars) and Ang II-treated animals (filled bars). 
* P < 0.05 vs Ctl; (unpaired t-test).
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suggest that endogenous Ang II exerts a tonic effect on
protein synthesis, as basal protein synthesis was inhibited
by irbesartan. However, this could also be due to the
hypotensive effect of irbesartan, as a change in hemody-
namic conditions is likely to influence the vessel wall.
Although our initial studies (5 hour administration) did
not show any influence of pressure reduction on vascular
protein synthesis per se, the longer period of hypotension
observed in the second series of experiments (24 hours of
Effect of Rapamycin (R at 0.1, 0.5 and 1.0 mg/kg) on aortic  and mesenteric leucine incorporation (expressed in cpm/mg  protein) Figure 3
Effect of Rapamycin (R at 0.1, 0.5 and 1.0 mg/kg) on aortic 
and mesenteric leucine incorporation (expressed in cpm/mg 
protein). The effect of the drug was tested in basal conditions 
and after angiotensin II (Ang)-induced protein synthesis. * P < 
0.05 vs Ctl; † P < 0.05 vs Ang II alone (ANOVA + 
Bonferroni).
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Effect of Irbesartan (Irb, 10 mg/kg s. twice at 12 hours inter- val) on basal and angiotensin II (Ang II)-stimulated aortic and  mesenteric leucine incorporation (expressed in cpm/mg  protein) Figure 4
Effect of Irbesartan (Irb, 10 mg/kg s.c. twice at 12 hours 
interval) on basal and angiotensin II (Ang II)-stimulated aortic 
and mesenteric leucine incorporation (expressed in cpm/mg 
protein). * P < 0.05 vs Ctl; † P < 0.05 vs Ang II alone 
(ANOVA + Bonferroni).
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Irbesartan) could still explain the reduction of protein
synthesis below physiological levels. Alternatively, unop-
posed AT2 receptors may reduce proliferation during AT1-
receptor blockade, as recently suggested by the reduced
efficacy of an AT1 receptor antagonist to prevent hypertro-
phy of coronary arteries in AT2 receptor null mice [31].
Interestingly, blockade of the ERK-1/2 or the rapamycin-
sensitive pathways did not influence basal protein synthe-
sis in large and small arteries, suggesting that these two
pathways, which respond to trophic stimuli, may not be
key elements in protein renewal under physiological con-
ditions, and therefore represent potential therapeutic
targets.
Because of the complex cellular microenvironment pro-
duced by local and circulating factors, the direct
relationship between an agonist and effector pathways
cannot be resolved when working in vivo. Furthermore,
signaling cascades and their kinetic of activation cannot
be studied as thoroughly as when using cell culture sys-
tems. Consequently, the aim of the present study was not
to characterize the signaling events up- or downstream of
the drugs' site of action, but to identify the pathways oper-
ating in vivo in arteries with distinct physiological func-
tions. Our interpretation of the data is based on the
current understanding of the mechanism of action of the
pharmacological agents that were used either to antago-
nize AT1-receptors or signaling events. In that respect, it
was recently shown that PD98059 can also affect ERK5
[32], the contribution of which is not known in our study.
It must also be underscored that the pharmacokinetic pro-
file of drugs affecting signaling cascades is seldom known
and the in vivo protocols have to be devised with short
duration between drug administration and end-point
measurement. This explains the rather late administration
of PD98059 and rapamycin with respect to Ang II infu-
sion. In fact, the effect of PD98059 on protein synthesis
was rather surprising, considering that in vitro Ang II-
induced activation of ERK-1/2 is transient in nature and
fades after 60 minutes [12]. However, it is consistent with
a report demonstrating sustained ERK-1/2 activity eleva-
tion in the aorta of Dahl and stroke-prone spontaneously
hypertensive rats [33]. Furthermore, we confirmed that
ERK-1/2 phosphorylation was elevated in the aorta after
21 hours of Ang II administration, corresponding to the
injection time of PD98059 or rapamycin. It is thus likely
that with constant infusion of Ang II in vivo ERK-1/2 acti-
vation follows a different kinetic than in synchronized
cells in culture receiving a single dose of Ang II. In small
arteries, we could not observe a sustained elevation of
ERK-1/2 phosphorylation, explaining, at least in part, the
lack of efficacy of PD98059 to reduce protein synthesis.
However, a recent report demonstrated that Ang II appli-
cation to isolated and pressurized small arteries did
enhance ERK-1/2 activity after 5 minutes [24]. In that
study, PD98059 reduced Ang II-induced vasoconstriction,
suggesting that ERK-1/2 may mediate different cellular
effects, and hence follow different activation kinetics in
large and small arteries. To further support this hypothe-
sis, we have recently reported that during acute NOS inhi-
bition, ERK1/2 activation is associated with protein
synthesis in large arteries [19], but with vasoconstriction
in small resistance arteries [34].
Conclusion
Our results obtained in in vivo conditions demonstrate
that Ang II administration at a non-pressor dose enhanced
vascular protein synthesis, a necessary first step towards
vascular hypertrophy/hyperplasia. In agreement with pre-
vious  in vitro studies, we show that both ERK1/2 and
rapamycin-sensitive signaling pathways are involved in
Ang II-induced increase in protein synthesis in vivo. In
contrast to what was suggested from in vitro studies, how-
ever, late inhibition of the signaling pathways was effec-
tive to reduce protein synthesis. In addition, we propose a
degree of vascular heterogeneity in the relative implica-
tion of ERK1/2 to mediate Ang II-induced protein
synthesis. This new information provides further insight
on the signaling events mediating hypertrophy of small
and large arteries that could be triggered by elevated levels
of circulating or local Ang II in pathological conditions.
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